Back to search
A Study of JNJ-95597528 in Participants With Moderate to Severe Atopic Dermatitis
Dermatitis, Atopic
Clinicaltrials.gov:
EU CTIS:
#2025-523464-20-00
Other:
#95597528ADM2001
Interested in this trial?
Subscribe or share this trial
Trials at a glance
Status
Enrolling
Condition
Dermatitis, Atopic
Trial type
Interventional
Trial phase
Phase 2
Investigational
product
product
JNJ-95597528
Placebo
Age
18+ years old
Biological sex
All
Placebo?
Yes
Trial start date
January 20, 2026
Trial end date
February 10, 2028
CT.gov ID
#NCT07230860
Share the trial ID with your doctor to see if trial participation is right for you. Participation depends on an independent medical assessment.
Countries:
- Argentina,
- Brazil,
- Canada,
- China,
- Japan,
- Taiwan,
- United States
Loading...
Enrolling
Niagara Falls, Ontario, Canada, L2H 1H5
Enrolling
Rolling Meadows, Illinois, United States, 60008
Enrolling
Ajax, Ontario, Canada, L1S7K8
Enrolling
Buenos Aires, Argentina, C1061AAS
Enrolling
Houston, Texas, United States, 77004
Enrolling
Rosario, Argentina, 2000
Enrolling
Rosario, Argentina, 2000
Enrolling
San Miguel de Tucumán, Argentina, T4000AXL
Enrolling
Curitiba, Brazil, 80030 110
Enrolling
Kaohsiung City, Taiwan, 833
Enrolling
Beijing, China, 100029
Enrolling
Taichung, Taiwan, 40201
Enrolling
Philadelphia, Pennsylvania, United States, 19114
Enrolling
Buenos Aires, Argentina, C1111
Enrolling
Indianapolis, Indiana, United States, 46250
Enrolling
Mississauga, Ontario, Canada, L4Y 4C5
Enrolling
Buenos Aires, Argentina, C1426
Enrolling
Calgary, Alberta, Canada, T2J 7E1
Enrolling
London, Ontario, Canada, N6H 5L5
Enrolling
Coral Gables, Florida, United States, 33134
Enrolling
Fountain Valley, California, United States, 92708
Enrolling
Santo André, Brazil, 09060 870
Enrolling
Detroit, Michigan, United States, 48202
Enrolling
Chengde, China, 067030
Enrolling
Porto Alegre, Brazil, 90035 903
Enrolling
Buenos Aires, Argentina, C1425BEN
Enrolling
Rio de Janeiro, Brazil, 20241 180
Enrolling
Buenos Aires, Argentina, B1643CRO
Enrolling
Córdoba, Argentina, X5000AAW
Enrolling
Tachikawa, Japan, 190 0023
Enrolling
Kaohsiung City, Taiwan, 813
Enrolling
Sakai, Japan, 590 0197
Enrolling
Nishiku, Japan, 593-8324
Enrolling
Taoyuan, Taiwan, 333
Enrolling
CABA, Argentina, C1128AAF
Enrolling
Matsudo, Japan, 271-0092
Enrolling
Taipei, Taiwan, 10048
Enrolling
Yokohama, Japan, 221 0825
Enrolling
Portland, Oregon, United States, 97210
Enrolling
São Paulo, Brazil, 04038 002
Enrolling
Santo André, Brazil, 09080-110
Enrolling
San Antonio, Texas, United States, 78213
Enrolling
Fargo, North Dakota, United States, 58103
Enrolling
Sanmenxia, China, 472000
Enrolling
Barrie, Ontario, Canada, L4M 7G1
Enrolling
Santa Ana, California, United States, 92701
Enrolling
New Taipei City, Taiwan, 235
Enrolling
tabashi City, Japan, 173-8606
Enrolling
Guangzhou, China, 510080
Enrolling
Xi'an, China, 710004
Enrolling
Taipei, Taiwan, 114202
Enrolling
Chengdu, China, 610041
Enrolling
Wuxi, China, 214100
Enrolling
Windsor, Ontario, Canada, N8T 1E6
Enrolling
Changsha, China, 410008
Enrolling
Richmond Hill, Ontario, Canada, L4B1L1
#
More than 50 sites in this region
#
More than 10 sites in this region
#
Less than 10 sites in this region
Individual sites
Access detailed information on the trial:
Clinical trials information
© Johnson & Johnson and its affiliates 2026
